Quick Answer
Sarepta Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $801.28 million for the year ending 2025.
- Sarepta Therapeutics, Inc. showed a decrease of -27.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Sarepta Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $36.74 million | Q3 2010: $35.97 million | Q1 2011: $23.28 million | Q2 2011: $54.19 million | Q3 2011: $46.36 million | Q1 2012: $30.57 million | Q2 2012: $24.49 million | Q3 2012: $37.99 million | Q1 2013: $167.92 million | Q2 2013: $156.19 million | Q3 2013: $273.64 million | Q1 2014: $49.10 million | Q2 2014: $102.75 million | Q3 2014: $52.30 million | Q1 2015: $74.44 million | Q2 2015: $69.54 million | Q3 2015: $55.82 million | Q1 2016: $38.00 million | Q2 2016: $111.82 million | Q3 2016: $395.14 million | Q1 2017: $274.72 million | Q2 2017: $168.35 million | Q3 2017: $617.63 million | Q1 2018: $557.23 million | Q2 2018: $410.38 million | Q3 2018: $209.70 million | Q1 2019: $732.19 million | Q2 2019: $808.59 million | Q3 2019: $724.83 million | Q1 2020: $1.76 billion | Q2 2020: $1.64 billion | Q3 2020: $1.47 billion | Q1 2021: $1.48 billion | Q2 2021: $1.70 billion | Q3 2021: $1.60 billion | Q1 2022: $1.23 billion | Q2 2022: $868.57 million | Q3 2022: $1.04 billion | Q1 2023: $871.67 million | Q2 2023: $851.93 million | Q3 2023: $541.93 million | Q1 2024: $427.29 million | Q2 2024: $383.62 million | Q3 2024: $197.86 million | Q1 2025: $240.87 million | Q2 2025: $510.60 million | Q3 2025: $613.08 million.
- Over the full 18 years of available data (2008 to 2025), Sarepta Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 7,059.4%.
- Historical annual values: Fiscal year 2025: $801.28 million | Fiscal year 2024: $1.10 billion | Fiscal year 2023: $428.43 million | Fiscal year 2022: $966.78 million | Fiscal year 2021: $2.12 billion | Fiscal year 2020: $1.50 billion | Fiscal year 2019: $835.08 million | Fiscal year 2018: $370.83 million | Fiscal year 2017: $599.69 million | Fiscal year 2016: $122.42 million | Fiscal year 2015: $80.30 million | Fiscal year 2014: $73.55 million | Fiscal year 2013: $256.97 million | Fiscal year 2012: $187.66 million | Fiscal year 2011: $39.90 million | Fiscal year 2010: $33.59 million | Fiscal year 2009: $48.28 million | Fiscal year 2008: $11.19 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: